Protocol Ledger

NCT05956587 · Phase II · RECRUITING

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Interventional Phase II clinical trial protocol NCT05956587 sponsored by Sichuan Baili Pharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-29 Enrollment: 121 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05956587
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)121 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05956587
Protocol FieldVerified Registry Value
NCT IdentifierNCT05956587
Consolidated Lead SponsorSichuan Baili Pharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment121 participants (ESTIMATED)
Registered Start Date2024-01-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI